Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Ursodeoxycholic Acid Market

Ursodeoxycholic Acid Market Size

  • Report ID: GMI6838
  • Published Date: Oct 2023
  • Report Format: PDF

Ursodeoxycholic Acid Market Size

Ursodeoxycholic Acid Market size was accounted for USD 581.7 million in 2022 and is likely to reach USD 1.4 billion by 2032 with CAGR of 10.1%. The growth in demand for ursodeoxycholic acid (UDCA) can be attributed to several factors, including the increasing prevalence of liver diseases such as primary biliary cholangitis and gallstones and the growing volume of research focused on UDCA.


Ursodeoxycholic Acid Market

To understand key trends  
Download Free Sample

UDCA has a well-established history of usage and is known for its ability to enhance liver function, reduce inflammation, and decelerate the progression of various liver diseases. Moreover, UDCA is readily available in various forms, including both branded and generic versions, and is offered in a wide range of strengths. This accessibility benefits both patients and healthcare providers ensuring a broader reach and ease of use, thereby promoting high market progress.


Ursodeoxycholic acid is an active pharmaceutical ingredient (API) that is isolated or synthesized and used as the primary therapeutic component in various pharmaceutical formulations. It is employed for its hepatoprotective (liver-protective) properties and its ability to dissolve cholesterol gallstones. UDCA is commonly used in medications for treating liver and gallbladder disorders, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and certain cases of gallstone disease.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Ursodeoxycholic acid industry size reached USD 581.7 million in 2022 and is poised to reach USD 1.4 billion by 2032 attributed to the increasing prevalence of liver diseases, such as primary biliary cholangitis and gallstones.

Synthetic segment is expected to be worth USD 958.6 million by 2032 driven by widespread utilization in the pharmaceutical and medical fields for its multitude advantages.

North America ursodeoxycholic acid market accounted for USD 203.7 million in revenue in 2022 and is expected to expand at notable CAGR through 2032 owing to increasing application due to the elevated prevalence of liver and gallbladder ailments UDCA.

Some of the top ursodeoxycholic acid companies are Daewoong Bio, ICE S.p.a., Merck KGa, Glenmark Pharmaceuticals Ltd., Dipharma Francis S.r.l., IOL Chemicals and Pharmaceuticals, Kimia Biosciences Ltd., Cerata Pharmaceuticals, and Changde Yungang Biotechnology Co. Ltd.,

Ursodeoxycholic Acid Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 14
  • Tables & Figures: 294
  • Countries covered: 22
  • Pages: 172
 Download Free Sample